The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Novo Nordisk, PayPal, and Dell Technologies are modestly priced growth stocks with a lot of potential to rise higher. Buying ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

By Mariam Sunny (Reuters) -U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' experimental weight-loss drug has helped overweight patients lose up to 17.7% of body ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.

The research, published in the Canadian Medical Association Journal (CMAJ) Monday, found that 32.7 per cent of Canadians ...

GLP-1 medications work by mimicking a hormone that regulates blood sugar, suppresses appetite and slows digestion, which in turn is said to 'reduce food noise,' particularly for those who struggle ...